Country: Canada
Language: English
Source: Health Canada
LACOSAMIDE
MARCAN PHARMACEUTICALS INC
N03AX18
LACOSAMIDE
150MG
TABLET
LACOSAMIDE 150MG
ORAL
250ML
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0152810003; AHFS:
APPROVED
2019-04-26
Page 1 of 48 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR MAR-LACOSAMIDE Lacosamide Film-coated tablets, 50 mg, 100 mg, 150 mg, 200 mg lacosamide, Oral Mfr. Std Antiepileptic ATC Code: N03AX18 Marcan Pharmaceuticals Inc. 2 Gurdwara Road, Suite #112, Ottawa ON K2E 1A2 Date of Initial Authorization: APR 24, 2019 Date of Revision: JAN 19, 2023 Submission Control Number: 271089 _Page 2 of 48 _ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, 7.1.1 Pregnant Women 01/2023 7 Warnings and Precautions, 7.1.2 Breast-feeding 01/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................. 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 4 4.1 Dosing Considerations ............................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment .......................................................... 5 4.4 Administration ........................................................................................................... 6 4.5 Missed Dose ............... Read the complete document